Abstract
Background
To analyze the ability of bevacizumab (Avastin) eye drops to inhibit corneal neovascularization. Design: interventional case series involving five patients (age: 42 ± 14 years).
Methods
Patients with aggressive corneal neovascularisation not responding to conventional therapy were treated with bevacizumab (Avastin) eye drops (5x/day; 5 mg/ml) for 0.5 to 6 months (mean: 3.6 ± 2; four patients with limbal stem cell deficiency [three due to chemical burns and one inherited] and one after perforating keratoplasty).
Results
Bevacizumab eye drops were well tolerated without obvious corneal side-effects. All five patients showed a reduction in the neovascularized area (decrease 48 ± 28%; 13–75%).
Conclusions
Bevacizumab eye drops seem to inhibit corneal neovascularization without obvious corneal epithelial side-effects.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Bakri SJ, Cameron JD, McCannel CA, Pulido JS, Marler RJ (2006) Absence of histologic retinal toxicity of intravitreal bevacizumab in a rabbit model. Am J Ophthalmol 142:162–164
Bock F, Onderka J, Dietrich T, Dietrich T, Bachmann B, Kruse FE, Cursiefen C (2007) Bevacizumab is a potent inhibitor of inflammatory angiogenesis and lymphangiogenesis in the cornea. Invest Ophthalmol Vis Sci 48:2545–2552
Bock F, König Y, Dietrich T, Zimmermann P, Baier M, Cursiefen C (2007) Inhibition of angiogenesis in the anterior chamber of the eye. Ophthalmologe 104:336–344
Chang JH, Gabison EE, Kato T, Azar DT (2001) Corneal neovascularization. Curr Opin Ophthalmol 12:242–249
Cursiefen C, Rummelt C, Küchle M (2000) Immunohistochemical localization of VEGF, TGFα and TGFβ1 in human corneas with neovascularization. Cornea 19:526–533
Cursiefen C, Rummelt C, Küchle M, Schlötzer-Schrehardt U (2003) Pericyte recruitment in human corneal angiogenesis. Br J Ophthalmol 87:101–106
Cursiefen C, Maruyama K, Liu Y, Chen L, Jackson D, Wiegand S, Dana MR, Streilein JW (2004) Inhibition of hem- and lymphangiogenesis after normal-risk corneal transplantation by neutralizing VEGF promotes graft survival. Invest Ophthalmol Vis Sci 45:2666–2673
Cursiefen C, Chen L, Saint-Geniez M, Hamrah P, Jin Y, Rashid S, Pytowski B, Streilein JW, Dana MR (2006) Nonvascular VEGF receptor 3 expression by corneal epithelium maintains avascularity and vision. Proc Natl Acad Sci USA 103:11405–11410
Manzano R, Peyman G, Khan P, Carvounis PE, Kivilcim M, Ren M, Lake JC, Chevez-Barrios P (2007) Inhibition of experimental corneal neovascularization by bevacizumab (Avastin). Br J Ophthalmol 91:804–807
Erdurmus M, Totan Y (2007) Subconjunctival bevacizumab for corneal neovascularization. Graefes Arch Clin Exp Ophthalmol 245:1577–1579
Kuhlmann A, Amann K, Schlötzer-Schrehardt U, Kruse FE, Cursiefen C (2005) Endothelin-1 and Eta/Etb-receptor protein and mRNA expression in normal and vascularized human corneas. Cornea 24:837–844
Acknowledgement
Funding: This study was supported by Interdisciplinary Center for Clinical Research (IZKF) Erlangen (A9) and ELAN Fonds University Erlangen. Financial disclosure: The authors have no financial interest in any of the products mentioned in the manuscript.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Bock, F., König, Y., Kruse, F. et al. Bevacizumab (Avastin) eye drops inhibit corneal neovascularization. Graefes Arch Clin Exp Ophthalmol 246, 281–284 (2008). https://doi.org/10.1007/s00417-007-0684-4
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00417-007-0684-4